Here, we describe a pharmacogenetics solution that permits to selectively and reversibly inactivate LC neurons applying Designer Receptors Exclusively Activated by Designer Medicine (DREADD). We clearly show that the expression in the hM4Di DREADD is often limited to noradrenergic LC neurons Which the amount of LC inhibition could be adjusted https://rowanddwof.muzwiki.com/6875718/article_under_review